Latest Insider Transactions at Travere Therapeutics, Inc. (TVTX)
This section provides a real-time view of insider transactions for Travere Therapeutics, Inc. (TVTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Travere Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Travere Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 04
2025
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,066
-1.25%
|
$21,320
$20.11 P/Share
|
|
Feb 03
2025
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
3,348
-5.0%
|
$66,960
$20.12 P/Share
|
|
Feb 03
2025
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,192
-5.45%
|
$103,840
$20.12 P/Share
|
|
Feb 03
2025
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,166
-4.04%
|
$103,320
$20.12 P/Share
|
|
Feb 03
2025
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,207
-4.7%
|
$84,140
$20.12 P/Share
|
|
Feb 03
2025
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
50,691
-10.53%
|
$1,013,820
$20.21 P/Share
|
|
Feb 03
2025
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
8,951
-9.09%
|
$170,069
$19.78 P/Share
|
|
Feb 03
2025
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
8,951
-8.55%
|
$170,069
$19.78 P/Share
|
|
Jan 31
2025
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
13,000
+16.25%
|
-
|
|
Jan 31
2025
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
21,500
+18.42%
|
-
|
|
Jan 31
2025
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
21,500
+14.39%
|
-
|
|
Jan 31
2025
|
Jula Inrig CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+25.12%
|
-
|
|
Jan 31
2025
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
130,000
+21.27%
|
-
|
|
Jan 31
2025
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
21,500
+17.93%
|
-
|
|
Jan 31
2025
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
BUY
Grant, award, or other acquisition
|
Direct |
21,500
+17.04%
|
-
|
|
Jan 23
2025
|
Roy D. Baynes |
SELL
Open market or private sale
|
Direct |
16,000
-34.04%
|
$320,000
$20.0 P/Share
|
|
Jan 23
2025
|
Roy D. Baynes |
BUY
Exercise of conversion of derivative security
|
Direct |
16,000
+25.4%
|
$272,000
$17.5 P/Share
|
|
Jan 22
2025
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
2,437
-2.85%
|
$46,303
$19.46 P/Share
|
|
Jan 22
2025
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,584
-1.47%
|
$28,512
$18.94 P/Share
|
|
Jan 22
2025
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
2,437
-3.07%
|
$46,303
$19.46 P/Share
|
|
Jan 22
2025
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
10,736
-2.97%
|
$203,984
$19.46 P/Share
|
|
Jan 22
2025
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
925
-1.68%
|
$16,650
$18.94 P/Share
|
|
Jan 22
2025
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
865
-1.16%
|
$15,570
$18.94 P/Share
|
|
Jan 06
2025
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
440
-0.73%
|
$7,920
$18.76 P/Share
|
|
Jan 03
2025
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,066
-3.34%
|
$39,254
$19.1 P/Share
|
|
Dec 26
2024
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
15,000
-21.45%
|
$255,000
$17.22 P/Share
|
|
Dec 26
2024
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+17.66%
|
$180,000
$12.67 P/Share
|
|
Nov 25
2024
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
12,090
-18.04%
|
$217,620
$18.3 P/Share
|
|
Nov 25
2024
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+18.29%
|
$180,000
$12.67 P/Share
|
|
Oct 04
2024
|
Gary A Lyons |
SELL
Open market or private sale
|
Direct |
40,000
-25.11%
|
$560,000
$14.75 P/Share
|
|
Oct 04
2024
|
Gary A Lyons |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+30.53%
|
$400,000
$10.48 P/Share
|
|
Sep 30
2024
|
Jeffrey A Meckler |
SELL
Open market or private sale
|
Direct |
40,000
-33.06%
|
$560,000
$14.06 P/Share
|
|
Sep 30
2024
|
Jeffrey A Meckler |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+24.84%
|
$400,000
$10.48 P/Share
|
|
Sep 10
2024
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
684
-1.09%
|
$8,208
$12.98 P/Share
|
|
Sep 09
2024
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,490
-3.23%
|
$27,390
$11.52 P/Share
|
|
Sep 09
2024
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,191
-1.99%
|
$24,101
$11.52 P/Share
|
|
Sep 09
2024
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,191
-3.38%
|
$24,101
$11.52 P/Share
|
|
Sep 09
2024
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
21,125
-5.51%
|
$232,375
$11.52 P/Share
|
|
Sep 09
2024
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
4,387
-5.28%
|
$48,257
$11.52 P/Share
|
|
Sep 09
2024
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
4,387
-4.94%
|
$48,257
$11.52 P/Share
|
|
Sep 05
2024
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
6,750
+8.05%
|
-
|
|
Sep 05
2024
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
6,750
+5.77%
|
-
|
|
Sep 05
2024
|
Jula Inrig CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
6,750
+9.43%
|
-
|
|
Sep 05
2024
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
32,500
+7.82%
|
-
|
|
Sep 05
2024
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
6,750
+7.52%
|
-
|
|
Sep 05
2024
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
BUY
Grant, award, or other acquisition
|
Direct |
6,750
+7.06%
|
-
|
|
Sep 04
2024
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
514
-0.73%
|
$4,626
$9.51 P/Share
|
|
May 08
2024
|
Roy D. Baynes |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+17.33%
|
-
|
|
May 08
2024
|
Suzanne Louise Bruhn |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+22.61%
|
-
|
|
May 08
2024
|
Timothy Coughlin |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+11.71%
|
-
|